@conference{dc93d1af5e9b44bf83bbd4872778a66c,
title = "CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)",
author = "Manmeet Ahluwalia and David Peereboom and Yasmeen Rauf and Justin Lathia and Tyler Alban and Cathy Schilero and Marci Ciolfi and Corey LaForest-Roys and Lakshmi Nayak and Eudocia Lee and Patrick Wen and David Reardon",
note = "You do not currently have access to this article. Subscription prices and ordering Don't already have an Oxford Academic account? Register CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM) - 24 Hours access; Neuro-oncology ; Conference date: 09-11-2020",
year = "2020",
month = nov,
day = "9",
doi = "10.1093/NEUONC/NOAA215.146",
language = "American English",
}